PMID- 36646286
OWN - NLM
STAT- MEDLINE
DCOM- 20230228
LR  - 20230228
IS  - 1873-4995 (Electronic)
IS  - 0168-3659 (Linking)
VI  - 354
DP  - 2023 Feb
TI  - Intradermal delivery of Cryj1 loaded in CpG DNA hydrogel for inhibiting allergic 
      reactions in mice.
PG  - 429-438
LID - S0168-3659(23)00038-X [pii]
LID - 10.1016/j.jconrel.2023.01.029 [doi]
AB  - Immunotherapy for allergic rhinitis alleviates symptoms associated with antigen 
      exposure by administering pathogenic antigens. However, many current 
      immunotherapies fail to induce sufficient immune responses, resulting in frequent 
      and prolonged hospital visits. Consequently, the development of more effective 
      immunotherapies is necessary. In this study, we focused on the skin, which is 
      rich in immune cells, as an administration site for inducing antigen-specific 
      immune responses. To efficiently and sustainably deliver the cedar pollen antigen 
      Cryj1 to immune cells, we attempted to load Cryj1 in an immunostimulatory CpG DNA 
      hydrogel, prepared using self-gelatinizable nucleic acid technology. In this 
      technology, the hydrogel became gelatinized by self-assembly of multiple 
      predesigned DNA units containing potent CpG motifs. Cryj1 loaded in the CpG DNA 
      hydrogel showed sustained release, was taken up by mouse macrophage-like RAW264.7 
      and mouse dendritic DC2.4 cells, and induced efficient production of 
      interleukin-12 after intradermal injection into mice. Intradermal injection of 
      Cryj1 loaded CpG DNA hydrogel into mice increased the production of 
      Cryj1-specific IgG while suppressing the production of immunoglobulin E (IgE) 
      antibodies. Furthermore, when Cryj1 was resensitized to mice, a stronger 
      induction of IgG production and suppression of IgE production was observed. These 
      results suggest that intradermal administration of Cryj1 loaded CpG DNA hydrogel 
      is a novel immunotherapy for allergic symptoms caused by cedar pollen and can be 
      used as a replacement for current immunotherapies.
CI  - Copyright (c) 2023 Elsevier B.V. All rights reserved.
FAU - Tanifuji, Takumi
AU  - Tanifuji T
AD  - Laboratory of Biopharmaceutics, Faculty of Pharmaceutical Sciences, Tokyo 
      University of Science, 2641 Yamazaki, Noda, Chiba 278-8510, Japan.
FAU - Nishimura, Moeka
AU  - Nishimura M
AD  - Laboratory of Biopharmaceutics, Faculty of Pharmaceutical Sciences, Tokyo 
      University of Science, 2641 Yamazaki, Noda, Chiba 278-8510, Japan.
FAU - Kusamori, Kosuke
AU  - Kusamori K
AD  - Laboratory of Biopharmaceutics, Faculty of Pharmaceutical Sciences, Tokyo 
      University of Science, 2641 Yamazaki, Noda, Chiba 278-8510, Japan.
FAU - Nishikawa, Makiya
AU  - Nishikawa M
AD  - Laboratory of Biopharmaceutics, Faculty of Pharmaceutical Sciences, Tokyo 
      University of Science, 2641 Yamazaki, Noda, Chiba 278-8510, Japan. Electronic 
      address: makiya@rs.tus.ac.jp.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20230118
PL  - Netherlands
TA  - J Control Release
JT  - Journal of controlled release : official journal of the Controlled Release 
      Society
JID - 8607908
RN  - 0 (Hydrogels)
RN  - 0 (Antigens)
RN  - 9007-49-2 (DNA)
RN  - 37341-29-0 (Immunoglobulin E)
RN  - 0 (Immunoglobulin G)
SB  - IM
MH  - Animals
MH  - Mice
MH  - *Hydrogels
MH  - *Hypersensitivity
MH  - Antigens
MH  - DNA
MH  - Immunoglobulin E
MH  - Immunoglobulin G
OTO - NOTNLM
OT  - Antigen
OT  - CpG motif
OT  - Immunotherapy
OT  - Intradermal delivery
OT  - Self-gelatinizable nucleic acid
OT  - Sustained release
COIS- Declaration of Competing Interest None.
EDAT- 2023/01/17 06:00
MHDA- 2023/03/03 06:00
CRDT- 2023/01/16 19:25
PHST- 2022/09/01 00:00 [received]
PHST- 2022/12/29 00:00 [revised]
PHST- 2023/01/11 00:00 [accepted]
PHST- 2023/01/17 06:00 [pubmed]
PHST- 2023/03/03 06:00 [medline]
PHST- 2023/01/16 19:25 [entrez]
AID - S0168-3659(23)00038-X [pii]
AID - 10.1016/j.jconrel.2023.01.029 [doi]
PST - ppublish
SO  - J Control Release. 2023 Feb;354:429-438. doi: 10.1016/j.jconrel.2023.01.029. Epub 
      2023 Jan 18.